AstraZeneca Does Not Expect Crestor Labeling Change Following Fatality

The company says that a fatality potentially caused by rhabdomyolysis appeared in spontaneous adverse event reporting for the cholesterol-lowering drug. AstraZeneca maintains that the evidence concerning the cause of death is more consistent with neuroleptic malignant syndrome.